JP2019530428A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530428A5
JP2019530428A5 JP2018568300A JP2018568300A JP2019530428A5 JP 2019530428 A5 JP2019530428 A5 JP 2019530428A5 JP 2018568300 A JP2018568300 A JP 2018568300A JP 2018568300 A JP2018568300 A JP 2018568300A JP 2019530428 A5 JP2019530428 A5 JP 2019530428A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
seq
composition according
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530428A (ja
JP7017013B2 (ja
Filing date
Publication date
Priority claimed from US15/201,429 external-priority patent/US10633433B2/en
Application filed filed Critical
Priority claimed from PCT/IB2017/053991 external-priority patent/WO2018007924A2/en
Publication of JP2019530428A publication Critical patent/JP2019530428A/ja
Publication of JP2019530428A5 publication Critical patent/JP2019530428A5/ja
Application granted granted Critical
Publication of JP7017013B2 publication Critical patent/JP7017013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568300A 2016-07-02 2017-06-30 抗トランスサイレチン抗体 Active JP7017013B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/201,429 2016-07-02
US15/201,429 US10633433B2 (en) 2015-01-28 2016-07-02 Anti-transthyretin antibodies
PCT/IB2017/053991 WO2018007924A2 (en) 2016-07-02 2017-06-30 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
JP2019530428A JP2019530428A (ja) 2019-10-24
JP2019530428A5 true JP2019530428A5 (cg-RX-API-DMAC7.html) 2020-08-13
JP7017013B2 JP7017013B2 (ja) 2022-02-08

Family

ID=59506313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568300A Active JP7017013B2 (ja) 2016-07-02 2017-06-30 抗トランスサイレチン抗体

Country Status (3)

Country Link
EP (1) EP3478716A2 (cg-RX-API-DMAC7.html)
JP (1) JP7017013B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018007924A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
AU2021272369A1 (en) 2020-05-12 2023-01-19 Neurimmune Ag Combination therapy for TTR amyloidosis
WO2022094152A1 (en) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anti-transthyretin antibodies and methods of use thereof
KR102623976B1 (ko) * 2021-08-30 2024-01-11 주식회사 뉴보텍 노후배관 보강 및 보수를 위한 보강신축관 및 이 보강신축관을 이용한 노후배관 보수방법
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
TW202434624A (zh) 2022-11-15 2024-09-01 瑞士商紐立慕公司 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CA2625839A1 (en) 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
AU2002361886A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Antibodies against the muc18 antigen
EP1567652B1 (de) 2002-11-29 2007-08-22 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
ATE433110T1 (de) 2004-11-10 2009-06-15 Boehringer Ingelheim Pharma Verwendung von durchflusszytometrischer analyse zur optimierung von zellbankingstrategien für cho-zellen
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
DK2126093T3 (da) 2007-03-02 2013-01-07 Boehringer Ingelheim Pharma Forbedring af proteinfremstilling
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI769570B (zh) * 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Similar Documents

Publication Publication Date Title
JP2019530428A5 (cg-RX-API-DMAC7.html)
JP2019532617A5 (cg-RX-API-DMAC7.html)
JP2019530427A5 (cg-RX-API-DMAC7.html)
JP6592059B2 (ja) アルファシヌクレインを認識するヒト化抗体
US20250263493A1 (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
JP2020536532A5 (cg-RX-API-DMAC7.html)
JP2018510617A5 (cg-RX-API-DMAC7.html)
RU2007139953A (ru) Антитела к ccr5 и их применение
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
KR102047248B1 (ko) 침식성 세포의 선택적 제거
CN112424223A (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
HRP20220918T1 (hr) Anti-transtiretinska antitijela
KR20190083356A (ko) 시누클레인병증의 치료를 위한 제제, 용도 및 방법
JP7221352B2 (ja) 抗pacap抗体
TW200840821A (en) Methods of purifying anti A beta antibodies
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
EA200970879A1 (ru) Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
JP2012501670A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
TWI713464B (zh) 針對Fcγ受體IIB及Fcε受體的新穎抗體
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
WO2014140374A2 (en) Monovalent cd27 antibodies
CN114751982B (zh) 抗人ngf抗体及其制备方法和用途
JP7772715B2 (ja) 治療用musk抗体